E2 ModerateModerate confidencePEM not requiredObservationalPeer-reviewedMachine draft
Impact of a mid-urethral synthetic mesh sling on long-term risk of systemic conditions in women with stress urinary incontinence: a national cohort study.
Muller, P, Gurol-Urganci, I, Thakar, R et al. · BJOG : an international journal of obstetrics and gynaecology · 2022 · DOI
Quick Summary
This study looked at whether a surgical mesh implant used to treat urinary leakage in women increases the risk of developing systemic diseases like autoimmune conditions, fibromyalgia, or ME/CFS. Researchers compared nearly 89,000 women who received mesh surgery to about 3,400 women who had surgery without mesh, following them for up to 10 years. The study found no evidence that mesh surgery increased the risk of these systemic conditions.
Why It Matters
ME/CFS patients and advocates have raised concerns about whether surgical mesh implants may trigger or exacerbate systemic autoimmune and post-viral conditions. This large, population-based study directly addresses those safety concerns by examining long-term risks, providing evidence relevant to informed decision-making for patients considering this common surgical procedure.
Observed Findings
- 10-year cumulative incidence of autoimmune disease, fibromyalgia, or ME/CFS was 8.1% (95% CI 7.9–8.3%) in the mesh group and 9.0% (95% CI 8.0–10.1%) in the non-mesh group.
- Adjusted hazard ratio was 0.89 (95% CI 0.79–1.01; P=0.07), suggesting no significant increased risk in the mesh group.
- Both treatment groups were well-matched at baseline for age, socioeconomic deprivation, comorbidity, and ethnicity.
- Sensitivity analysis examining only autoimmune diseases as the outcome returned similar results.
Inferred Conclusions
- Synthetic mesh slings do not appear to increase the long-term risk of systemic conditions including autoimmune disease, fibromyalgia, and ME/CFS.
- Current evidence does not support claims that mid-urethral mesh surgery causes systemic disease.
Remaining Questions
- Does mesh-related systemic disease occur only in specific patient subgroups with particular genetic or immunological characteristics?
- Why are the point estimates lower in the mesh group, and could this reflect unmeasured confounding or selection bias?
- How reliable are hospital admission records for capturing ME/CFS diagnoses, given the condition's variable severity and underdiagnosis?
- Could mesh-related inflammation trigger disease in individuals with pre-existing immunological vulnerabilities not captured by baseline comorbidity assessments?
What This Study Does Not Prove
This study does not prove that mesh surgery is entirely safe for all patients, nor does it exclude the possibility of mesh-related complications in specific subgroups. Observational studies cannot definitively establish causation, and reliance on hospital admission records may miss milder cases of ME/CFS or autoimmune disease not requiring hospitalization. The study also cannot rule out individual sensitivity or rare adverse events occurring in a small number of patients.
Tags
Symptom:Fatigue
Method Flag:Mixed Cohort
Metadata
- DOI
- 10.1111/1471-0528.16917
- PMID
- 34524725
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →